Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
#Public Trading
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
#Acquisition #Management Changes
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
#Acquired-by, Management Changes
Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022
#Acquired-by #Management Changes
Advaxis and Ayala Pharmaceuticals Complete Merger
#Acquisition #Management Changes
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
#Customers
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
#Acquired-by #Management Changes #Public Trading
Ayala Pharmaceuticals raises $55m in Nasdaq IPO
#Investment
Ayala Pharmaceuticals Announces Pricing of Initial Public Offering
#Public Trading
Ayala Pharma files for Nasdaq IPO
#Public Trading
Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma
undefined
Ayala Pharmaceuticals Headed for Nasdaq IPO
#Investment #Public Trading
Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO
undefined
Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)
#None
Ayala Pharma nabs AbbVie cancer exec Gordon as CMO
undefined
ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration
#Partners
Cancer drug developer Ayala Pharmaceuticals raises $30m
#Investment
Ayala Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference
undefined
Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast Cancer
undefined
FDA Grants Orphan Drug Designation to Ayala's AL101 for Potential Treatment of Adenoid Cystic Carcinoma (ACC)
undefined
Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma
#Customers
Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals
#Investment
https://www.marketwatch.com/press-release/ayala-pharmaceuticals-signs-deal-to-develop-and-commercialize-al102-in-combination-with-bcma-targeting-agents-in-multiple-myeloma-2018-12-20
undefined
https://www.marketwatch.com/press-release/ayala-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-study-of-lead-product-candidate-al101-for-adenoid-cystic-carcinoma-with-notch-activated-mutations-2018-12-17
undefined
Cancer drug developer Ayala Pharmaceuticals raises $17m
#Investment
Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments
undefined